Literature DB >> 946596

Study of Leo-1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia.

J H Kaufman, G L Hanjura, A Mittelman, C W Aungst, G P Murphy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 946596

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  8 in total

1.  Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).

Authors:  M Freund; S Wunsch-Zeddies; M Schäfers; J Wysk; I Seidel; W Hiddemann; A R Hanauske; H Link; H J Schmoll; H Poliwoda
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

Review 2.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.

Authors:  T Hatschek; L Baldetorp; J Carstensen; L Håkansson; T Möller; B Nilsson; B Termander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

4.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

Authors:  E Musch; M Malek; J Peter-Katalinic; H Egge; H Rink; B Lathan; E Riedel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria.

Authors:  D R Gandara; C B George; C A Ries; M M Koretz; J P Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Prednimustine in adult acute myeloid leukaemia.

Authors:  L Brandt; I Könyves
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.

Authors:  D R Gandara; C A Ries; S A Schiff; C B George; J P Lewis; M M Koretz; S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.